Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A

doi:10.57740/a51f-3605

Science Portal

v2.1.5153.produswest2

About MSF Science Portal

About

Frequently Asked Questions (FAQs)

v2.1.5153.produswest2

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial | Conference Material / Video | MSF Science Portal

Science Portal

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Countries

Subject Area

Languages

DOI

Published Date

Conference

Science Portal

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Similar Content

Countries

Subject Area

Languages

DOI

Published Date

Conference